1-tert-butyl 3-ethyl 3-benzyl-4-oxopiperidine-1,3-dicarboxylate | 219324-21-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-tert-butyl 3-ethyl 3-benzyl-4-oxopiperidine-1,3-dicarboxylate
• 英文别名: 3-benzyl-4-oxo-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester；3-benzyl-4-oxopiperidine-1,3-dicarboxylic acid 1-tert-butyl 3-ethyl ester；1-O-tert-butyl 3-O-ethyl 3-benzyl-4-oxopiperidine-1,3-dicarboxylate
• CAS: 219324-21-7
• 化学式: C₂₀H₂₇NO₅
• 分子量: 361.438
• InChiKey: NTXNVZIFOWTIBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-tert-butyl 3-ethyl 3-benzyl-4-oxopiperidine-1,3-dicarboxylate 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 48.0h， 以87%的产率得到1-Boc-3-苄基-4-哌啶酮
  参考文献：
  名称：

  EP1553084

  摘要：

  公开号：
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基乙酰胺 为溶剂， 反应 1.0h， 生成 1-tert-butyl 3-ethyl 3-benzyl-4-oxopiperidine-1,3-dicarboxylate
  参考文献：
  名称：

  Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists

  摘要：

  Systematic SAR optimization of the GPR119 agonist lead 1, derived from an internal HTS campaign, led to compound 29. Compound 29 displays significantly improved in vitro activity and oral exposure, leading to GLP1 elevation in acutely dosed mice and reduced glucose excursion in an OGTT study in rats at doses >= 10 mg/kg. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.10.010

文献信息

• Treatment of insulin resistance with growth hormone secretagogues
  申请人：Pfizer Inc.

  公开号：US06448263B1

  公开（公告）日：2002-09-10

  This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

  这项发明涉及治疗哺乳动物的胰岛素抵抗方法，包括向该哺乳动物施用化合物I的有效量，其中变量在规范中定义，或其立体异构混合物、对映异构体富集物、对映异构体纯物、对映体富集物或对映体纯异构体，或其药学上可接受的盐和前药。化合物I是生长激素分泌素，因此对于增加内源生长激素水平是有用的。在另一个方面，这项发明提供了一些在合成上述化合物中有用的中间体，以及对合成所述中间体和化合物I有用的某些过程。这项发明进一步涉及方法，包括向人类或其他动物施用功能性生长抑素拮抗剂，如α-2肾上腺素受体激动剂和化合物I的组合。
• Piperidine derivative, process for producing the same, and use
  申请人：Ikeura Yoshinori

  公开号：US20060167052A1

  公开（公告）日：2006-07-27

  The present invention provides a compound represented by the formula: wherein Ar is an aryl group, an aralkyl group or an aromatic heterocyclic group, each of which may be substituted, R 1 is a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group or an optionally substituted heterocyclic group, X is an oxygen atom or an optionally lo substituted imino group, Z is an optionally substituted methylene group, Ring A is an optionally further substituted piperidine ring, and Ring B is an optionally substituted aromatic ring, provided that when Z is a methylene group substituted with an oxo group, R 1 is not a methyl group, and 15 when Z is a methylene group substituted with a methyl group, Ring B is a substituted aromatic ring, or a salt thereof, which is a novel piperidine derivative having excellent antagonistic action for a tachykinin receptor and useful as a medicament, particularly an agent for preventing and/or treating urinary frequency and/or urinary incontinence.

  本发明提供了一种化合物，其表示为以下式子：其中Ar是芳基、芳基烷基或芳香杂环基，每个基团都可以被取代，R1是氢原子、可选取代的碳氢基团、酰基或可选取代的杂环基团，X是氧原子或可选取代的亚胺基团，Z是可选取代的亚甲基团，环A是可选进一步取代的哌啶环，环B是可选取代的芳香环，但当Z是取代有氧基的亚甲基团时，R1不是甲基基团，而当Z是取代有甲基基团的亚甲基团时，环B是取代的芳香环，或其盐。该化合物是一种新型哌啶衍生物，具有优异的缓解速激肽受体拮抗作用，可用作药物，特别是用作预防和/或治疗尿频和/或尿失禁的药剂。
• Treatment of insulin resistance
  申请人：Carpino Philip Albert

  公开号：US06867202B1

  公开（公告）日：2005-03-15

  This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and th compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

  本发明涉及治疗哺乳动物胰岛素抵抗的方法，其包括向该哺乳动物施用公式I的化合物的有效量，其中变量在规范中定义，或其立体异构混合物，对映异构体富集体，对映异构体纯异构体，对映异构体纯异构体，或其药学上可接受的盐和前药。公式I的化合物是生长激素分泌素，因此对于增加内源性生长激素水平非常有用。在另一个方面，本发明提供了某些中间体，这些中间体在合成上述化合物和公式I的化合物的某些过程中非常有用。本发明进一步涉及方法，包括向人类或其他动物施用功能性生长抑素拮抗剂（如α-2肾上腺素受体激动剂）和公式I的化合物的组合。
• PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1553084A1

  公开（公告）日：2005-07-13

  The present invention provides a compound represented by the formula:    wherein Ar is an aryl group, an aralkyl group or an aromatic heterocyclic group, each of which may be substituted, R1 is a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group or an optionally substituted heterocyclic group, X is an oxygen atom or an optionally substituted imino group, Z is an optionally substituted methylene group, Ring A is an optionally further substituted piperidine ring, and Ring B is an optionally substituted aromatic ring, provided that when Z is a methylene group substituted with an oxo group, R1 is not a methyl group, and when Z is a methylene group substituted with a methyl group, Ring B is a substituted aromatic ring, or a salt thereof, which is a novel piperidine derivative having excellent antagonistic action for a tachykinin receptor and useful as a medicament, particularly an agent for preventing and/or treating urinary frequency and/or urinary incontinence.

  本发明提供了一种由式表示的化合物： 其中 Ar 是芳基、芳烷基或芳香杂环基团，每个基团均可被取代；R1 是氢原子、任选取代的烃基、酰基或任选取代的杂环基团；X 是氧原子或任选取代的亚氨基；Z 是任选取代的亚甲基；环 A 是任选进一步取代的哌啶环；环 B 是任选取代的芳香环、当 Z 是被氧代基团取代的亚甲基时，R1 不是甲基；当 Z 是被甲基取代的亚甲基时，环 B 是被取代的芳香环，或其盐，这是一种新型哌啶衍生物，对快速激肽受体有很好的拮抗作用，可用作药物，特别是预防和/或治疗尿频和/或尿失禁的药物。
• TREATMENT OF INSULIN RESISTANCE WITH GROWTH HORMONE SECRETAGOGUES
  申请人：Pfizer Products Inc.

  公开号：EP1000085B1

  公开（公告）日：2005-09-28